Journal article icon

Journal article

Association between daptomycin dosing and in-hospital mortality in patients with vancomycin-resistant Enterococcus faecium bloodstream infection

Abstract:
Background: Vancomycin-resistant Enterococcus faecium (VREfm) bloodstream infections (BSIs) pose significant management challenges with uncertainties relating to the optimal daptomycin dose for treatment. Methods: A retrospective cohort study of adult patients receiving ≥3 days of definitive treatment for a first episode VREfm BSI between 2015 and 2022 was undertaken. Daptomycin doses were classified as low (≤7.9 mg/kg), medium (8.0 to 9.9 mg/kg) or high (≥10 mg/kg). We aimed to assess the association between daptomycin dose and in-hospital 30-day all-cause mortality in addition to other clinical outcomes (hospital length of stay, transfer to the ICU within 48 hours and microbiological failure). In addition, we undertook a comparative analysis of mortality and other outcomes in vanB VREfm BSIs receiving definitive daptomycin and teicoplanin treatment. Results: A total of 191 patients received definitive daptomycin (n = 111) or teicoplanin (n = 80) therapy and were included in two separate analyses. Of the 111 daptomycin patients, most received high-dose daptomycin (59.5%), with 29.7% and 10.8% receiving medium and low doses, respectively. All-cause 30-day in-hospital mortality was 17.1% and there was no association between daptomycin dose groups and in-hospital 30-day mortality (log rank P = 0.369). Microbiological failure was associated with dose (P = 0.036): 33.3% in the low dose group, 12.1% for medium and 19.7% for high. No mortality difference was observed between vanB VREfm BSIs treated with daptomycin or teicoplanin [adjusted cause-specific hazard ratio 0.67 (95% CI: 0.28–1.59)]. Conclusions: In this contemporary study of predominantly high daptomycin doses, there was no association between daptomycin dose and 30-day in-hospital mortality but we did observe an association with microbiological failure.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1093/jacamr/dlaf172

Authors

More by this author
Role:
Author
ORCID:
0000-0002-9969-3972
More by this author
Role:
Author
ORCID:
0000-0001-6590-6127
More by this author
Role:
Author
ORCID:
0000-0002-6284-2022
More by this author
Role:
Author
ORCID:
0000-0003-2370-2438
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-8409-4248


Publisher:
Oxford University Press
Journal:
JAC-Antimicrobial Resistance More from this journal
Volume:
7
Issue:
5
Article number:
dlaf172
Publication date:
2025-10-09
Acceptance date:
2025-09-08
DOI:
EISSN:
2632-1823
ISSN:
2632-1823


Language:
English
Pubs id:
2300641
Local pid:
pubs:2300641
Source identifiers:
3356559
Deposit date:
2025-10-09
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP